Safety, immune response, and replication of the rVSV-ΔG-ZEBOV-GP Ebola vaccine in children aged 1-12 in Gabon

In the rVSVΔG-ZEBOV-GP group, 70% of children had detectable vector copies in plasma by day 3.

• Children aged 1-12 years showed stronger and longer vector replication in plasma and saliva after vaccination compared to adults.
• In the rVSVΔG-ZEBOV-GP group, 7% of children had detectable vector copies in saliva by day 14, with no detection by day 28.
• Transitory but significantly higher adverse events were observed in the rVSVΔG-ZEBOV-GP vaccinated group.
• Both rVSVΔG-ZEBOV-GP and varicella-zoster virus vaccines induced seroconversion by day 28.
• Sustainable IgG antibody titres were maintained in both groups by day 365, with peak avidity and neutralization functions observed at day 28.

Simplified